Market capitalization | $12.87b |
Enterprise Value | $11.39b |
P/E (TTM) P/E ratio | 188.28 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.95 |
P/S ratio (TTM) P/S ratio | 3.34 |
P/B ratio (TTM) P/B ratio | 4.27 |
Revenue growth (TTM) Revenue growth | 9.78% |
Revenue (TTM) Revenue | $3.86b |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
25 Analysts have issued a Incyte forecast:
25 Analysts have issued a Incyte forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 598 598 |
75%
75%
|
|
Depreciation and Amortization | 83 83 |
22%
22%
|
|
Stock Compensation | 216 216 |
15%
15%
|
|
Operating Cash Flow | 496 496 |
49%
49%
|
|
Investments | 47 47 |
39%
39%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | 464 464 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Head office | United States |
CEO | Herve Hoppenot |
Employees | 2,524 |
Founded | 1991 |
Website | www.incyte.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.